Cart
sales@molnova.com
OSSK-630513
CAS No. 2054944-79-3
OSSK-630513( OSSK-3 | OSSK 630513 )
Catalog No. M13187 CAS No. 2054944-79-3
A novel potent CFTR potentiator with Kd of 31.7 nM; potentially serves as lead compound for development of new drugs for the treatment of cystic fibrosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameOSSK-630513
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel potent CFTR potentiator with Kd of 31.7 nM; potentially serves as lead compound for development of new drugs for the treatment of cystic fibrosis.
-
DescriptionA novel potent CFTR potentiator with Kd of 31.7 nM; potentially serves as lead compound for development of new drugs for the treatment of cystic fibrosis.Cystic Fibrosis Preclinical.
-
In Vitro——
-
In Vivo——
-
SynonymsOSSK-3 | OSSK 630513
-
PathwayApoptosis
-
TargetCFTR
-
RecptorCFTR
-
Research AreaOther Indications
-
IndicationFibrosis
Chemical Information
-
CAS Number2054944-79-3
-
Formula Weight457.122
-
Molecular FormulaC16H15Br2N3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(N/N=C/C1=CC(Br)=C(O)C(Br)=C1O)CNC2=CC=CC(C)=C2
-
Chemical Name(E)-N'-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cui G, et al. Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L192-207.
molnova catalog
related products
-
WAY-326766
WAY-326766 increases ion transport through mutant CFTR and can be used to alter the lifespan of eukaryotes.WAY-326766 can be used to treat cystic fibrosis (CF).
-
UCCF-853
UCCF-853 is a small-molecule CFTR modulator that can be used to study cystic fibrosis.
-
DNDS
DNDS is a channel blocker of voltage-dependent cystic fibrosis transmembrane conductance regulator (CFTR).
